Holen Sie sich die Stockscreener-App
0.9781
1.04%
0.0109
Schlusskurs vom Vortag:
$0.9672
Offen:
$1.04
24-Stunden-Volumen:
2.77M
Relative Volume:
2.75
Marktkapitalisierung:
$81.41M
Einnahmen:
$24.99M
Nettoeinkommen (Verlust:
$-118.64M
KGV:
-0.7466
EPS:
-1.31
Netto-Cashflow:
$-100.25M
1W Leistung:
-2.27%
1M Leistung:
+20.62%
6M Leistung:
+81.99%
1J Leistung:
-29.69%
1-Tages-Spanne:
$0.9175
$1.0899
1-Wochen-Bereich:
$0.7896
$1.0899
52-Wochen-Spanne:
$0.4471
$1.54
Adicet Bio Inc Stock (ACET) Company Profile
Firmenname
Adicet Bio Inc
Sektor
Branche
Telefon
617-482-2333
Adresse
131 DARTMOUTH STREET, BOSTON
Vergleichen Sie ACET mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.9779 | 148.23M | 24.99M | -118.64M | -100.25M | -1.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.45 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.07 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-30 | Fortgesetzt | Guggenheim | Buy |
| 2024-09-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-06-27 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-03-31 | Eingeleitet | SMBC Nikko | Outperform |
| 2022-03-08 | Eingeleitet | Truist | Buy |
| 2022-03-04 | Eingeleitet | Jefferies | Buy |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2021-04-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-04-08 | Eingeleitet | Guggenheim | Buy |
| 2020-11-04 | Eingeleitet | B. Riley Securities | Buy |
| 2020-10-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-16 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Adicet Bio Inc Aktie (ACET) Neueste Nachrichten
How sentiment analysis helps forecast Adicet Bio Inc.Quarterly Trade Report & Community Verified Swing Trade Signals - newser.com
Why Adicet Bio Inc. (1IJA) stock could rally strongly2025 Market Outlook & AI Driven Stock Movement Reports - newser.com
How strong is Adicet Bio Inc. stock revenue growth2025 Earnings Impact & Free Technical Pattern Based Buy Signals - newser.com
Orbimed advisors buys Adicet Bio (ACET) shares worth $5 million - Investing.com India
Orbimed advisors buys Adicet Bio (ACET) shares worth $5 million By Investing.com - Investing.com UK
What moving averages say about Adicet Bio Inc.2025 Price Targets & Entry Point Confirmation Alerts - newser.com
Multi factor analysis applied to Adicet Bio Inc.July 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Adicet Bio’s SWOT analysis: cell therapy stock faces pivotal moment By Investing.com - Investing.com Australia
What RSI levels show for Adicet Bio Inc. (1IJA) stockJuly 2025 Reactions & High Conviction Investment Ideas - newser.com
Guggenheim Maintains Adicet Bio (ACET) Buy Recommendation - Nasdaq
Adicet Bio’s SWOT analysis: cell therapy stock faces pivotal moment - Investing.com India
Adicet Bio (NASDAQ:ACET) Earns Sell (E+) Rating from Weiss Ratings - MarketBeat
Adicet Bio Inc Stock Analysis and ForecastBreakout Stock Watch & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Adicet Bio stock holds steady as Citizens reiterates Market Perform - Investing.com
Adicet Bio reports positive results from ADI-001 autoimmune trial By Investing.com - Investing.com Canada
Adicet Bio Receives Nasdaq Extension for Compliance - TipRanks
Guggenheim raises Adicet Bio stock price target on positive lupus data - Investing.com
Adicet Bio Announces $80 Million Offering - citybiz
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2 - Benzinga
Are Medical Stocks Lagging Exact Sciences (EXAS) This Year? - sharewise.com
Adicet Bio prices $80 million stock offering at $1 per share - Investing.com Nigeria
Adicet Bio reports positive results from ADI-001 autoimmune trial - Investing.com
Adicet Bio Announces Major Stock Offering Agreement - TipRanks
Adicet Bio Reports Promising Phase 1 Study Results - TipRanks
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) - NewsBreak: Local News & Alerts
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering - The Joplin Globe
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Adicet Bio, Inc. (NASDAQ:ACET) Receives $5.33 Consensus Target Price from Brokerages - Defense World
What analysts say about Adicet Bio Inc stockMid Cap Growth Trends & Free Explosive Portfolio Gains - earlytimes.in
Evaluating Adicet Bio Inc. with trendline analysisWeekly Trade Recap & Daily Profit Maximizing Tips - newser.com
Why Adicet Bio Inc. stock remains on buy listsMarket Activity Report & Reliable Volume Spike Alerts - newser.com
Can Adicet Bio Inc. (1IJA) stock reach $200 price targetQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
What to expect from Adicet Bio Inc. in the next 30 days2025 Historical Comparison & AI Forecasted Entry/Exit Points - newser.com
Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is Adicet Bio Inc a good long term investmentPrice Action Trading & High Profit Trading Alerts - earlytimes.in
What momentum shifts mean for Adicet Bio Inc.July 2025 Movers & Community Verified Swing Trade Signals - newser.com
Finanzdaten der Adicet Bio Inc-Aktie (ACET)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):